Can a gene therapy restore natural hearing after cochlear implants?

NCT ID NCT07752888

First seen Aug 07, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This trial tests an experimental gene therapy called EA0010 in children aged 1 to 17 with hearing loss caused by mutations in the OTOF gene, who already have cochlear implants. The therapy is injected into one ear and aims to deliver a working copy of the OTOF gene to inner ear cells. The study will check whether the treatment is safe and whether it can improve hearing beyond what the implant provides.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
EA0010, an investigational gene therapy using two AAV vectors carrying the OTOF gene, injected into the inner ear
What this could lead to
If successful, this could enable children with OTOF-related hearing loss to hear without relying on cochlear implants, potentially restoring more natural hearing.
What could go wrong
This is an early, very small trial (one participant), so results may not generalize. Risks include immune reactions, inflammation, or the therapy not improving hearing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COCHLEAR IMPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.